ClinicalTrials.gg
RecruitingNCT05677204AchTendUpdated Dec 11, 2023

Influencing Factors of Acute Achilles Tendinopathy in Runners

An observational study in Achilles Tendinopathy, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Laval University · Observational

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
95
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Tendinopathy with a site in Canada — 3 open to participants now, 3 under way, none of them phase 3. Tendinopathy · Canada.

Started
2022
with 1 other
Observational
3 of 17
1 open now
Registered
15th of 17
by date
Lead sponsor
2 of 17
Laval University

Among the 17 studies in Tendinopathy with a site in Canada, this one is one of 2 that started in 2022, is one of 3 observational ones, and was the 15th registered.

Tendinopathy

399 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

3 of the 17 studies in Tendinopathy with a site in Canada are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Tendinopathy with a site in Canada, or all of them as a file.
02

Study summary

Achilles tendinopathy is highly prevalent in runners, but its evolution is not easily predictable. The aim of this study is to evaluate the impact of clinical and social factors on the prognosis of acute (less than 3 months) Achilles tendinopathy in runners. Runners will be evaluated in person twice. At their first visit, data related to their training (frequency, intensity, ...), their running pattern (cadence, foot contact angle) and shoes (minimalist index) will be collected. Moreover, an ultrasound evaluation of Achilles tendon will be performed. At one, two and three months after their initial evaluation, participants will receive a link to complete an online survey about their pain. Three months after their initial evaluation, a second ultrasound of Achilles tendon will be performed.

Read the detailed description

At their first visit, participants will read and sign the consent form. They will then fill self-report questionnaires about their pain (using the Victorian Institute of Sport Assessment for Achilles tendinopathy score and visual analog scale) and its impact on their activities, and they will be questioned on their training habits. Then, participants will be asked to run on a treadmill for five minutes at a comfortable speed. During the run, video will be recorded to evaluate to cadence and the foot contact angle. Finally, an ultrasound of Achilles tendon will be performed to evaluate thickness, area, echogenicity and inflammation of the tendon. All the images will be revised by a physician qualified in diagnostic ultrasound and the tendinopathy will be graded according to Matthew and al. model.

One, two and three months after their initial visit, participants will receive a questionnaire by email to quantify their pain. Moreover, three months after their initial visit, participants will come back in person to the laboratory. Information about their pain, training and treatment will be collected and a second ultrasound analysis will be performed.

Statistical analysis: Baseline data will be compared using independent t-test or a Mann-Whitney U test. Significant variables in the univariate analysis will be considered as potential predictor variables. Logistic analysis regression will then be performed to identify predictive factors for pain chronicity.

03

Conditions studied

  • Achilles Tendinopathy

Browse trials for

Keywords

  • Runners
  • Acute
  • Prognosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Runners from Québec city region with Achilles tendon pain for less than three months

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Achilles tendon pain for less than three months
  • Run at least five kilometers per week
  • Have a score on the Victorian Institute of Sports Assessment of Achilles tendinopathy of 80 or less
  • Consent to the study

Exclusion criteria

Exclusion Criteria:

  • History of Achilles tendon surgery or rupture
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
95 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acute Achilles tendinopathy

    No intervention will be given

06

What researchers measure

Primary outcomes

  1. Pain graded on the visual analog scale

    Pain graded on a 0 to 10 visual analog scale

    Time frame: At three months

  2. Victorian Institute of Sports Assessment for Achilles tendinopathy (VISA-A) questionnaire

    Pain impact score between 0 (heavily affected) and 100 (asymptomatic)

    Time frame: At three months

Secondary outcomes

  1. Thickness of the Achilles tendon

    Ultrasound evaluation of the tendon

    Time frame: At three months

  2. Area of the Achilles tendon

    Ultrasound evaluation of the tendon

    Time frame: At three months

  3. Aspect of the tendon at ultrasound evaluation graded according to Matthew and al

    Ultrasound evaluation of the tendon

    Time frame: At three months

07

Study locations

1 of 1 sites recruiting
  • Center for Interdisciplinary Research in Rehabilitation and Social Integration (CIRRIS)
    Quebec City, Quebec G1M 2S8, Canada
    Recruiting
08

References and documents

Publications

  • Altman AR, Davis IS. A kinematic method for footstrike pattern detection in barefoot and shod runners. Gait Posture. 2012 Feb;35(2):298-300. doi: 10.1016/j.gaitpost.2011.09.104. Epub 2011 Nov 8. PubMed 22075193 ↗
  • Esculier JF, Dubois B, Dionne CE, Leblond J, Roy JS. A consensus definition and rating scale for minimalist shoes. J Foot Ankle Res. 2015 Aug 19;8:42. doi: 10.1186/s13047-015-0094-5. eCollection 2015. PubMed 26300981 ↗
  • Matthews W, Ellis R, Furness JW, Rathbone E, Hing W. Staging achilles tendinopathy using ultrasound imaging: the development and investigation of a new ultrasound imaging criteria based on the continuum model of tendon pathology. BMJ Open Sport Exerc Med. 2020 Mar 25;6(1):e000699. doi: 10.1136/bmjsem-2019-000699. eCollection 2020. PubMed 32341798 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jun 2023, 12 months.

Of 19 observational studies under Tendinopathy, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2022
First posted
Jan 10, 2023
StartActual
Jun 1, 2022
Primary completionActual
Jun 30, 2023
CompletionEst.
Dec 2023
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05677204
Lead sponsor
Laval University
Responsible party
Jean-Sébastien Roy (Principal Investigator, Laval University) — Principal investigator
First posted
Jan 10, 2023
Start date
Jun 1, 2022
Primary completion
Jun 30, 2023
Completion
Dec 2023 (estimated)
Last update
Dec 11, 2023

Study contacts

Jean-Sebastien Roy, PT,PhD
Contact
jean-sebastien.roy@fmed.ulaval.ca
1-418-529-9141 ext. 6005
Marie-Helene Lavallee-Bourget
Contact
marie-helene.lavallee-bourget.1@ulaval.ca
1-418 265-1721

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion